Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025828 · ClinicalTrials.gov registry record · Phase 4
Adrenocorticotropic Hormone in Membranous Nephropathy
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03025828 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 5 participants.
The verdict
NCT03025828, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy. Acthar is a hormone that stimulates steroid production from small glands above the kidneys. It has direct protective effects on the kidney and is currently approved by the FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of action are not entirely understood and will be studied in the present trial.
Interventions
- DRUG ACTHar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-19 |
| Est. Completion | 2020-12-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03025828
The ClinicalTrials.gov registry entry for NCT03025828 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACTHar is the first listed.
NCT03025828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03025828 about?
NCT03025828 is a clinical study titled "Adrenocorticotropic Hormone in Membranous Nephropathy". The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy. Acthar is a hormone that stimulates steroid production from small glands above the kidneys. It has direct prot...
What is the current status of trial NCT03025828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-03-19. Estimated completion is 2020-12-16.
What interventions are being tested in trial NCT03025828?
The interventions under investigation include: ACTHar (DRUG).
Who is sponsoring clinical trial NCT03025828?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.